Hey
Just to be clear im not trying to russle any jimmies here - but I have pretty much only seen positive reviews on Alphamine, and after reviewing the formula it appears N-Coumaroyldopamine is the main beta 2 agonist in the formula.
Cooper back in early 2012 made the following comment:
"Originally Posted by Mr.Cooper69 View Post
N-coumaryldopamine fails both pharmacokinetically and pharmacodynamically.
Source: Brain Cell"
Now all PES appear to be pimping it as "flex appeal"...
Has there been new findings on this ultra-selective beta-2 agonist to justify the complete 360?
Cheers
Just to be clear im not trying to russle any jimmies here - but I have pretty much only seen positive reviews on Alphamine, and after reviewing the formula it appears N-Coumaroyldopamine is the main beta 2 agonist in the formula.
Cooper back in early 2012 made the following comment:
"Originally Posted by Mr.Cooper69 View Post
N-coumaryldopamine fails both pharmacokinetically and pharmacodynamically.
Source: Brain Cell"
Now all PES appear to be pimping it as "flex appeal"...
Has there been new findings on this ultra-selective beta-2 agonist to justify the complete 360?
Cheers